CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024

CS Diagnostics Group (OTC: FZRO) signed a landmark agreement to sell and transfer tangible and intangible assets, including patents, for the CS Protect-Hydrogel to CS Diagnostics Corp. The hydrogel-based tissue spacer, designed for radiation therapy, increases the distance between healthy tissue and cancer cells, protecting healthy tissues from high radiation doses.

The CS Protect-Hydrogel received a valuation exceeding 960 million, based on its discounted commercial value. This valuation was supported by a similar product acquired by Boston Scientific (NYSE: BSX) for $500 million in 2018, including additional compensation through distribution revenues. Consequently, CS Diagnostics Corp. issued 110 million shares of common stock on September 27, 2023, representing a $500 million transaction payment.

On July 31, CS Diagnostics Corp. announced compliance with FINRA Rule 6432 after submitting Form 211 through Glendale Securities. This submission does not constitute approval of the issuer or its securities but allows the company to start quoting its stock. CS Diagnostics Corp., a global wholesaler of pharmaceuticals and leading medical technology manufacturer, has been supplying health ministries, practices, clinics, and specialists for over a decade.

Other notable companies in the healthcare sector include: UniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE), and Travere Therapeutics, Inc. (NASDAQ: TVTX).

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cs-diagnostics-otc-fzro-acquisitions-announced-landmark-agreement-signed-moving-forward-through-2024]
Country: United States
Website: http://www.thestreetreports.com



This release was published on openPR.